Jinsong Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3946717/publications.pdf

Version: 2024-02-01

160 papers	13,434 citations	17405 63 h-index	24915 109 g-index
164 all docs	164 docs citations	164 times ranked	22326 citing authors

#	Article	IF	Citations
1	Giant cells: Linking McClintockâ€™s heredity to early embryogenesis and tumor origin throughout millennia of evolution on Earth. Seminars in Cancer Biology, 2022, 81, 176-192.	4.3	16
2	Polyploid giant cancer cells: An emerging new field of cancer biology. Seminars in Cancer Biology, 2022, 81, 1-4.	4.3	25
3	The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Seminars in Cancer Biology, 2022, 81, 132-144.	4.3	23
4	Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports, 2022, 38, 110301.	2.9	4
5	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. IScience, 2022, 25, 103923.	1.9	23
6	Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Human Pathology, 2022, 127, 136-145.	1.1	7
7	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers, 2022, 14, 2498.	1.7	12
8	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	2.9	90
9	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Reports, 2021, 34, 108726.	2.9	27
10	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers, 2021, 13, 704.	1.7	3
11	Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene, 2021, 40, 3533-3547.	2.6	101
12	Protein citrullination as a source of cancer neoantigens. , 2021, 9, e002549.		24
13	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Human Pathology, 2021, 113, 20-27.	1.1	13
14	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis, 2021, 10, 65.	2.1	30
15	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3545-3555.	1.2	5
16	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	3.2	31
17	The â€œlife codeâ€: A theory that unifies the human life cycle and the origin of human tumors. Seminars in Cancer Biology, 2020, 60, 380-397.	4.3	70
18	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0

#	Article	IF	Citations
19	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1â€“Mediated Cell Death in Uterine Cancer. Molecular Cancer Therapeutics, 2020, 19, 1943-1954.	1.9	5
20	Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?. Annals of Diagnostic Pathology, 2020, 46, 151505.	0.6	12
21	Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific Reports, 2020, 10, 520.	1.6	9
22	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	2.9	69
23	Guidelines and definitions for research on epithelialâ€“mesenchymal transition. Nature Reviews Molecular Cell Biology, 2020, 21, 341-352.	16.1	1,195
24	Cytoplasmic SIRT1 inhibits cell migration and invasion by impeding epithelialâ€“mesenchymal transition in ovarian carcinoma. Molecular and Cellular Biochemistry, 2019, 459, 157-169.	1.4	18
25	Ovarian Epithelial Carcinogenesis. , 2019, , 121-139.		2
26	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell, 2019, 35, 851-867.e7.	7.7	156
27	Inhibition of miR-328â€“3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. Cancer Research, 2019, 79, 2314-2326.	0.4	68
28	Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clinical Chemistry, 2019, 65, 674-683.	1.5	77
29	Mechanisms of nuclear content loading to exosomes. Science Advances, 2019, 5, eaax8849.	4.7	176
30	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports, 2019, 9, 17589.	1.6	12
31	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Letters, 2019, 442, 464-474.	3.2	70
32	GATA6: a new predictor for prognosis in ovarian cancer. Human Pathology, 2019, 86, 163-169.	1.1	19
33	Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer. Current Cancer Drug Targets, 2019, 19, 360-367.	0.8	107
34	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Molecular Cell, 2018, 69, 279-291.e5.	4.5	138
35	RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy, 2018, 14, 637-653.	4.3	43
36	Carcinoma of the urethra. Human Pathology, 2018, 72, 35-44.	1.1	37

#	Article	IF	Citations
37	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	5.8	151
38	The dualistic origin of human tumors. Seminars in Cancer Biology, 2018, 53, 1-16.	4.3	105
39	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	15.2	372
40	Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research, 2017, 77, 2903-2913.	0.4	106
41	Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic Oncology Reports, 2017, 20, 93-96.	0.3	5
42	Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 2017, 295, 697-704.	0.8	4
43	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	5.8	169
44	Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Science Translational Medicine, 2017, 9, .	5.8	286
45	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	2.9	32
46	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research, 2017, 23, 1945-1954.	3.2	54
47	Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death and Disease, 2017, 8, e3070-e3070.	2.7	72
48	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 2017, 8, 96496-96505.	0.8	49
49	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget, 2016, 7, 25930-25948.	0.8	49
50	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget, 2016, 7, 72845-72859.	0.8	13
51	Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. Archives of Pathology and Laboratory Medicine, 2016, 140, 148-152.	1.2	19
52	Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nature Communications, 2016, 7, 11363.	5.8	74
53	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports, 2016, 15, 1493-1504.	2.9	75
54	MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology and Oncology, 2016, 9, 112.	6.9	17

#	Article	IF	Citations
55	Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer, 2016, 16, 582.	1.1	24
56	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism, 2016, 24, 685-700.	7.2	293
57	B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Human Pathology, 2016, 57, 1-6.	1.1	32
58	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	3.0	51
59	Renal cell carcinoma metastatic to the ovary or fallopian tube: a clinicopathological study of 9 cases. Human Pathology, 2016, 51, 96-102.	1.1	14
60	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes and Cancer, 2016, 7, 60-72.	0.6	34
61	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget, 2016, 7, 3018-3032.	0.8	14
62	Tumor necrosis factor-Î± and interferon-Î³ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFÎºB. Oncotarget, 2016, 7, 14871-14884.	0.8	44
63	A Fraction of CD133+ CNE2 Cells Is Made of Giant Cancer Cells with Morphological Evidence of Asymmetric Mitosis. Journal of Cancer, 2015, 6, 1236-1244.	1.2	26
64	Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opinion on Therapeutic Targets, 2015, 19, 1307-1317.	1.5	36
65	Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Modern Pathology, 2015, 28, 1613-1620.	2.9	60
66	The Homeoprotein DLX4 Stimulates NF-ÎºB Activation and CD44-Mediated Tumorâ€“Mesothelial Cell Interactions in Ovarian Cancer. American Journal of Pathology, 2015, 185, 2298-2308.	1.9	18
67	Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biology and Therapy, 2015, 16, 1548-1556.	1.5	57
68	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	7.7	94
69	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE, 2015, 10, e0131833.	1.1	28
70	Gastric-type mucinous adenocarcinoma of the uterine cervix with neoadjuvant therapy mimicking clear cell carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 11798-803.	0.5	2
71	Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. International Journal of Cancer, 2014, 134, 508-518.	2.3	84
72	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research, 2014, 16, 3417.	2.2	21

#	Article	IF	Citations
73	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.4	59
74	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	5.8	103
75	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	5.8	112
76	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	7.7	252
77	Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation. Medical Oncology, 2014, 31, 52.	1.2	22
78	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	2.9	43
79	miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget, 2014, 5, 10816-10829.	0.8	91
80	Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. International Journal of Clinical and Experimental Pathology, 2014, 7, 848-57.	0.5	23
81	Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Human Pathology, 2013, 44, 2373-2384.	1.1	50
82	Interleukin-1Î² Promotes Ovarian Tumorigenesis through a p53/NF-ÎºB-Mediated Inflammatory Response in Stromal Fibroblasts. Neoplasia, 2013, 15, 409-IN18.	2.3	73
83	Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Letters, 2013, 333, 205-212.	3.2	58
84	miR-106a Represses the Rb Tumor Suppressor p130 to Regulate Cellular Proliferation and Differentiation in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2013, 11, 1314-1325.	1.5	42
85	CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Human Pathology, 2013, 44, 1882-1889.	1.1	32
86	Loss of p53 in stromal fibroblasts promotes epithelial cell invasion through redox-mediated ICAM1 signal. Free Radical Biology and Medicine, 2013, 58, 1-13.	1.3	13
87	<scp>RAS</scp> promotes tumorigenesis through genomic instability induced by imbalanced expression of Auroraâ€A and <scp>BRCA2</scp> in midbody during cytokinesis. International Journal of Cancer, 2013, 133, 275-285.	2.3	34
88	The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes and Cancer, 2013, 4, 460-475.	0.6	51
89	iTRAQ-Based Proteomic Analysis of Polyploid Giant Cancer Cells and Budding Progeny Cells Reveals Several Distinct Pathways for Ovarian Cancer Development. PLoS ONE, 2013, 8, e80120.	1.1	70
90	Transformation of the Human Ovarian Surface Epithelium with Genetically Defined Elements. Methods in Molecular Biology, 2013, 1049, 377-392.	0.4	0

#	Article	IF	Citations
91	VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. American Journal of Translational Research (discontinued), 2013, 5, 336-46.	0.0	48
92	Mucinous borderline tumor involving fallopian tube: case report and review of the literature. International Journal of Clinical and Experimental Pathology, 2013, 6, 962-5.	0.5	3
93	Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biology, 2012, 10, e1001326.	2.6	128
94	CD133 expression associated with poor prognosis in ovarian cancer. Modern Pathology, 2012, 25, 456-464.	2.9	123
95	Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle, 2012, 11, 2107-2113.	1.3	36
96	Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Human Pathology, 2012, 43, 1405-1412.	1.1	58
97	Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Letters, 2012, 326, 176-182.	3.2	40
98	MiRâ€182 overexpression in tumourigenesis of highâ€grade serous ovarian carcinoma. Journal of Pathology, 2012, 228, 204-215.	2.1	138
99	Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells. Experimental Cell Research, 2012, 318, 1641-1648.	1.2	39
100	Analogues and Derivatives of Oncrasin-1, a Novel Inhibitor of the C-Terminal Domain of RNA Polymerase II and Their Antitumor Activities. Journal of Medicinal Chemistry, 2011, 54, 2668-2679.	2.9	49
101	RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases, 2011, 2, 202-210.	0.7	32
102	Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer. Neoplasia, 2011, 13, 393-405.	2.3	136
103	Overexpression of the Î² Subunit of Human Chorionic Gonadotropin Promotes the Transformation of Human Ovarian Epithelial Cells and Ovarian Tumorigenesis. American Journal of Pathology, 2011, 179, 1385-1393.	1.9	30
104	HMGA2 Overexpression-Induced Ovarian Surface Epithelial Transformation Is Mediated Through Regulation of EMT Genes. Cancer Research, 2011, 71, 349-359.	0.4	132
105	AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Modern Pathology, 2011, 24, 836-845.	2.9	54
106	Expression and Function of Androgen Receptor Coactivator p44/Mep50/WDR77 in Ovarian Cancer. PLoS ONE, 2011, 6, e26250.	1.1	35
107	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle, 2010, 9, 140-146.	1.3	21
108	HMGA2: A Potential Biomarker Complement to P53 for Detection of Early-stage High-grade Papillary Serous Carcinoma in Fallopian Tubes. American Journal of Surgical Pathology, 2010, 34, 18-26.	2.1	53

#	Article	IF	Citations
109	Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth. Molecular Pharmaceutics, 2010, 7, 775-785.	2.3	94
110	CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. Clinical Cancer Research, 2010, 16, 3875-3886.	3.2	152
111	Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. Clinical Cancer Research, 2010, 16, 3171-3181.	3.2	106
112	Stanniocalcin 1 and Ovarian Tumorigenesis. Journal of the National Cancer Institute, 2010, 102, 812-827.	3.0	107
113	Ovarian cancer: pathology, biology, and disease models. Frontiers in Bioscience - Landmark, 2009, Volume, 2089.	3.0	88
114	Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Molecular Cancer Therapeutics, 2009, 8, 2036-2045.	1.9	99
115	Biological Significance of Prolactin in Gynecologic Cancers. Cancer Research, 2009, 69, 5226-5233.	0.4	83
116	Inflammation: A hidden path to breaking the spell of ovarian cancer. Cell Cycle, 2009, 8, 3107-3111.	1.3	52
117	Epithelial ovarian cancer: Focus on genetics and animal models. Cell Cycle, 2009, 8, 731-735.	1.3	28
118	REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle, 2009, 8, 780-786.	1.3	43
119	Inhibiting JNK Dephosphorylation and Induction of Apoptosis by Novel Anticancer Agent NSC-741909 in Cancer Cells. Journal of Biological Chemistry, 2009, 284, 16948-16955.	1.6	22
120	ALDH1 expression correlates with favorable prognosis in ovarian cancers. Modern Pathology, 2009, 22, 817-823.	2.9	139
121	PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern Pathology, 2009, 22, 1243-1250.	2.9	76
122	CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. Human Pathology, 2009, 40, 252-258.	1.1	71
123	Activation of KLF8 Transcription by Focal Adhesion Kinase in Human Ovarian Epithelial and Cancer Cells. Journal of Biological Chemistry, 2008, 283, 13934-13942.	1.6	67
124	PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. Cancer Research, 2008, 68, 9302-9310.	0.4	62
125	The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium. Cancer Research, 2008, 68, 1110-1118.	0.4	74
126	Identification of a Small Molecule with Synthetic Lethality for K-Ras and Protein Kinase C Iota. Cancer Research, 2008, 68, 7403-7408.	0.4	80

#	Article	IF	Citations
127	Up-regulation of Tumor Susceptibility Gene 101 Protein in Ovarian Carcinomas Revealed by Proteomics Analyses. Molecular and Cellular Proteomics, 2007, 6, 294-304.	2.5	34
128	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis, 2007, 28, 174-182.	1.3	62
129	Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. International Journal of Cancer, 2007, 120, 81-90.	2.3	180
130	Sheep stromalâ€epithelial cell interactions and ovarian tumor progression. International Journal of Cancer, 2007, 121, 2346-2354.	2.3	2
131	Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Modern Pathology, 2007, 20, 1078-1084.	2.9	14
132	Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Modern Pathology, 2006, 19, 1414-1420.	2.9	45
133	Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by Î²-phenylethyl isothiocyanate. Cancer Cell, 2006, 10, 241-252.	7.7	994
134	Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer, 2006, 106, 1925-1932.	2.0	83
135	The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006, 107, 2730-2740.	2.0	119
136	Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2404-2413.	3.2	52
137	Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomibâ€“Induced Apoptosis in Oncogenic K-ras-Transformed Cells. Cancer Research, 2006, 66, 6072-6079.	0.4	19
138	RASâ€Mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB Journal, 2006, 20, 497-499.	0.2	32
139	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16472-16477.	3.3	292
140	Use of Rasâ€Transformed Human Ovarian Surface Epithelial Cells as a Model for Studying Ovarian Cancer. Methods in Enzymology, 2006, 407, 660-676.	0.4	15
141	Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers. Methods in Enzymology, 2006, 407, 455-468.	0.4	58
142	Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nature Medicine, 2005, 11, 531-537.	15.2	265
143	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24, 6174-6184.	2.6	32
144	Mitochondrial Manganese-Superoxide Dismutase Expression in Ovarian Cancer. Journal of Biological Chemistry, 2005, 280, 39485-39492.	1.6	235

#	Article	IF	Citations
145	The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochemical and Biophysical Research Communications, 2005, 336, 952-960.	1.0	25
146	Expression of the Tumor Suppressor Gene ARHI in Epithelial Ovarian Cancer Is Associated with Increased Expression of p21WAF1/CIP1 and Prolonged Progression-Free Survival. Clinical Cancer Research, 2004, 10, 6559-6566.	3.2	59
147	Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry. Cancer Research, 2004, 64, 4577-4584.	0.4	120
148	Activated Signal Transducer and Activator of Transcription (STAT) 3. Cancer Research, 2004, 64, 3550-3558.	0.4	239
149	Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression. Journal of Biological Chemistry, 2004, 279, 4339-4345.	1.6	101
150	A Genetically Defined Model for Human Ovarian Cancer. Cancer Research, 2004, 64, 1655-1663.	0.4	259
151	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Medicine, 2004, 10, 1251-1256.	15.2	463
152	Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathology, 2004, 17, 75-80.	2.9	55
153	Validation of tissue microarray technology in ovarian carcinoma. Modern Pathology, 2004, 17, 790-797.	2.9	112
154	Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). Journal of Translational Medicine, 2004, 2, 23.	1.8	127
155	Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathology, 2004, 17, 75-80.	2.9	5
156	Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. International Journal of Oncology, 2004, 24, 879-84.	1.4	3
157	Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene, 2003, 22, 2396-2404.	2.6	76
158	Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene, 2003, 22, 5694-5701.	2.6	110
159	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clinical Cancer Research, 2003, 9, 3660-6.	3.2	51
160	Overexpression of the thymosin Î²-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene, 2001, 20, 6700-6706.	2.6	51